Page 1077 - He News Today

After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR /KEYNOTE-581 trial Final results will be presented at ASCO 2023... | May 25, 2023

GoodRx Holdings, Inc. , a leading digital healthcare platform, today announced that executives from the Company will be presenting at the Jefferies Healthcare Conference in New York, NY on Thursday,... | May 25, 2023

VMPL

PALM BEACH GARDENS, Fla., May 25, 2023 -- Dycom Industries, Inc. today announced that the Company will be participating in the following investor conferences: On Thursday, June 1, 2023, the... | May 25, 2023

CONCORD, Calif., May 25, 2023 -- AssetMark Financial Holdings, Inc. today announced that the Company will be attending the 43rd Annual William Blair Growth Stock Conference on June 6th and 7th in... | May 25, 2023

Incyte today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting held... | May 25, 2023

71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also... | May 25, 2023

Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conference: Jefferies Healthcare Conference on Wednesday, June 7 at 11:00am ET The live... | May 25, 2023

<b>May 25, 2023 : Silex Systems Limited </b>is pleased to provide the attached presentation that will be delivered by James Dobchuk, Global Laser Enrichment’s Chief Commercial... | May 25, 2023

- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER... | May 25, 2023